Innoviva Return on Tangible Equity 2012-2026 | INVA
Current and historical return on tangible equity values for Innoviva (INVA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Innoviva Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-03-31 | $0.29B | $0.72B | 40.83% |
| 2025-09-30 | $0.13B | $0.55B | 23.12% |
| 2025-06-30 | $0.04B | $0.46B | 8.29% |
| 2025-03-31 | $-0.06B | $0.44B | -13.85% |
| 2024-12-31 | $0.02B | $0.45B | 5.12% |
| 2024-09-30 | $0.07B | $0.44B | 14.78% |
| 2024-06-30 | $0.15B | $0.42B | 34.52% |
| 2024-03-31 | $0.18B | $0.39B | 46.70% |
| 2023-12-31 | $0.18B | $0.35B | 52.10% |
| 2023-09-30 | $0.05B | $0.31B | 16.12% |
| 2023-06-30 | $0.23B | $0.31B | 75.79% |
| 2023-03-31 | $0.23B | $0.35B | 67.19% |
| 2022-12-31 | $0.22B | $0.39B | 55.48% |
| 2022-09-30 | $0.29B | $0.45B | 65.47% |
| 2022-06-30 | $0.10B | $0.48B | 20.68% |
| 2022-03-31 | $0.19B | $0.46B | 40.35% |
| 2021-12-31 | $0.27B | $0.53B | 50.26% |
| 2021-09-30 | $0.31B | $0.55B | 56.41% |
| 2021-06-30 | $0.27B | $0.56B | 47.45% |
| 2021-03-31 | $0.25B | $0.58B | 43.38% |
| 2020-12-31 | $0.22B | $0.51B | 43.88% |
| 2020-09-30 | $0.22B | $0.44B | 48.65% |
| 2020-06-30 | $0.23B | $0.38B | 59.80% |
| 2020-03-31 | $0.19B | $0.32B | 59.11% |
| 2019-12-31 | $0.16B | $0.27B | 58.90% |
| 2019-09-30 | $0.38B | $0.22B | 168.99% |
| 2019-06-30 | $0.38B | $0.13B | 307.63% |
| 2019-03-31 | $0.40B | $0.02B | 1666.67% |
| 2018-12-31 | $0.40B | $-0.08B | -499.68% |
| 2018-09-30 | $0.19B | $-0.18B | -105.70% |
| 2018-06-30 | $0.17B | $-0.21B | -80.10% |
| 2018-03-31 | $0.15B | $-0.24B | -60.25% |
| 2017-12-31 | $0.13B | $-0.27B | -48.86% |
| 2017-09-30 | $0.10B | $-0.30B | -33.47% |
| 2017-06-30 | $0.09B | $-0.34B | -27.22% |
| 2017-03-31 | $0.07B | $-0.36B | -20.31% |
| 2016-12-31 | $0.06B | $-0.36B | -16.32% |
| 2016-09-30 | $0.04B | $-0.36B | -10.58% |
| 2016-06-30 | $0.02B | $-0.35B | -5.18% |
| 2016-03-31 | $-0.01B | $-0.33B | 1.51% |
| 2015-12-31 | $-0.02B | $-0.31B | 6.56% |
| 2015-09-30 | $-0.04B | $-0.28B | 14.55% |
| 2015-06-30 | $-0.06B | $-0.30B | 18.95% |
| 2015-03-31 | $-0.11B | $-0.32B | 35.28% |
| 2014-12-31 | $-0.17B | $-0.22B | 76.47% |
| 2014-09-30 | $-0.20B | $-0.09B | 224.31% |
| 2014-06-30 | $-0.23B | $0.08B | -275.08% |
| 2014-03-31 | $-0.20B | $0.19B | -104.28% |
| 2013-12-31 | $-0.17B | $0.18B | -92.27% |
| 2013-09-30 | $-0.15B | $0.15B | -101.85% |
| 2013-06-30 | $-0.14B | $0.12B | -116.81% |
| 2013-03-31 | $-0.14B | $0.15B | -91.95% |
| 2012-12-31 | $-0.02B | $0.13B | -13.77% |
| 2012-09-30 | $-0.02B | $0.07B | -34.16% |
| 2012-06-30 | $-0.02B | $0.01B | -163.27% |
| 2012-03-31 | $-0.01B | $-0.04B | 18.08% |
| 2011-12-31 | $-0.12B | $-0.05B | 219.91% |
| 2011-09-30 | $-0.10B | $-0.04B | 268.49% |
| 2011-06-30 | $-0.09B | $-0.06B | 154.39% |
| 2011-03-31 | $-0.08B | $-0.08B | 105.99% |
| 2010-12-31 | $-0.08B | $-0.10B | 83.58% |
| 2010-09-30 | $-0.09B | $-0.14B | 61.16% |
| 2010-06-30 | $-0.09B | $-0.15B | 58.37% |
| 2010-03-31 | $-0.09B | $-0.16B | 55.97% |
| 2009-12-31 | $-0.09B | $-0.17B | 50.97% |
| 2009-09-30 | $-0.08B | $-0.15B | 51.55% |
| 2009-06-30 | $-0.08B | $-0.14B | 55.42% |
| 2009-03-31 | $-0.08B | $-0.13B | 64.34% |
| 2008-12-31 | $-0.09B | $-0.12B | 81.21% |
| 2008-09-30 | $-0.11B | $-0.10B | 112.69% |
| 2008-06-30 | $-0.12B | $-0.08B | 157.42% |
| 2008-03-31 | $-0.14B | $-0.05B | 261.68% |
| 2007-12-31 | $-0.16B | $-0.03B | 617.48% |
| 2007-09-30 | $-0.16B | $0.01B | -2523.08% |
| 2007-06-30 | $-0.17B | $0.04B | -422.36% |
| 2007-03-31 | $-0.17B | $0.08B | -219.14% |
| 2006-12-31 | $-0.17B | $0.11B | -150.57% |
| 2006-09-30 | $-0.17B | $0.11B | -155.25% |
| 2006-06-30 | $-0.17B | $0.11B | -153.85% |
| 2006-03-31 | $-0.16B | $0.11B | -143.11% |
| 2005-12-31 | $-0.14B | $0.11B | -126.27% |
| 2005-09-30 | $-0.13B | $0.15B | -89.19% |
| 2005-06-30 | $-0.11B | $0.15B | -76.90% |
| 2005-03-31 | $-0.11B | $0.12B | -97.60% |
| 2004-12-31 | $-0.10B | $0.08B | -136.91% |
| 2004-09-30 | $-0.09B | $0.03B | -333.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |